29 October 2009
Promethera® Biosciences Raises EUR 5.3 million through Series A Capital Round to Develop Promising Technology in the Treatment of Liver Diseases.The spin-off from Université catholique de Louvain is now ready to complete pre-clinical studies for an innovative stem cell therapy to treat unmet medical needs and to circumvent liver transplantation.
Read more on Promethera's website